药房技术人员对获得高成本心力衰竭药物治疗的影响
Morgan S Augustine1, Erika Nicolsen1, Alexander Reed2
1Duke University Hospital, Durham, NC, USA.
The Annals of pharmacotherapy
|February 19, 2026
概括
药房技术人员改善了对高成本的心力衰竭药物,萨库比特里尔-瓦尔萨坦和-葡萄糖共运输体2抑制剂 (SGLT2i) 的获取. 这种干预增加了心力衰竭患者的药物处方和满足率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 针对心力衰竭的指导指导医疗 (GDMT) 难以获得,特别是由于成本,萨库比特里尔-瓦尔萨坦和-葡萄糖共运输体2抑制剂 (SGLT2i) 具有挑战性.
- 药房技术人员可以在改善心力衰竭患者获得药物的过程中发挥关键作用.
研究的目的:
- 评估将药房技术人员整合到门诊心力衰竭诊所对患者获得高成本GDMT的影响.
- 具体评估了获得sacubitril-valsartan和SGLT2i的机会.
主要方法:
- 使用了回顾性,前后队列研究设计.
- 成年心力衰竭患者有资格接受sacubitril-valsartan和SGLT2i在药房技术人员实施之前和之后进行了分析.
- 主要结局是sacubitril-valsartan和/或SGLT2i的处方和填充率,控制了处方药的覆盖率.
主要成果:
- 在实施后,获得萨库比特利-瓦尔萨坦和/或SGLT2i的可用性显著增加,从71.9%增加到86.5% (OR = 2.46,P = 0.02).
- 在二次结果中没有发现显著差异,包括获得其他心力衰竭药物或住院率.
- 药房技术人员平均每位协助患者花费66.4分钟.
结论:
- 药房技术人员在心力衰竭诊所的实施显著提高了患者获得萨库比特里尔-瓦尔萨坦和SGLT2i的机会.
- 需要进一步的前性研究来探索药房技术人员对心力衰竭管理中的临床结果的影响.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
428
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
428
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:30Heart Failure V: Medical Management
388
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
388
01:29Cardiomyopathy V: Interprofessional Care
501
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
501
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25